Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 27 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1811 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In return for US$50 M upfront and up to US$515 M in precommercialisation milestone payments, Baxter International has licensed European commercialisation rights to Onconova Therapeutics’ lead anticancer therapy rigosertib...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS